Genmab A/S (GMAB) Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesutecan for the treatment of adults with endometrial cancer.
The regulatory decision was supported by results from the Phase 1/2 RAINFOL-01 study that showed encouraging responses in heavily pretreated endometrial cancer patients.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.